ANDA 76970, held by Ranbaxy. Fexofenadine Hydrochloride.
As of Nov 22, 2026, ANDA 76970 (Fexofenadine Hydrochloride), held by Ranbaxy, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 2007 | Original application | Tentative approval | None posted |
| Fexofenadine Hydrochloride30MG · tablet; oral | Fexofenadine Hydrochloride | None (tentative approval) |
| Fexofenadine Hydrochloride60MG · tablet; oral | Fexofenadine Hydrochloride | None (tentative approval) |
| Fexofenadine Hydrochloride180MG · tablet; oral | Fexofenadine Hydrochloride | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters